Studies to Gain Insight How the Drugs PCSK9-inhibitors and Statins Affect Cholesterol and Bile Acid Metabolism

Launched by REGION STOCKHOLM · Nov 16, 2023

Keywords

ClinConnect Summary

This clinical trial is looking to understand how two different medications, evolocumab and atorvastatin, affect cholesterol levels and bile acid metabolism in the body. Both drugs are used to help manage cholesterol, but this study will focus on how they work in healthy men between the ages of 65 and 74. By studying their effects closely, researchers hope to gain important insights into how these treatments can benefit patients in the future.

To participate in the trial, volunteers must be healthy men over 18 years old and should not have any serious health conditions like heart disease, diabetes, or cancer. Participants will take part in several sessions where they will receive either of the medications, and researchers will monitor their cholesterol and bile acid levels. The study is not currently recruiting participants, but it is an important step in exploring how these medications can help manage cholesterol more effectively.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male
• • \>18 years of age
• Exclusion Criteria:
• • Cardiovascular disease
• • Cerebrovascular disease (e.g. stroke, prior aneurysm)
• • Pulmonary disease (e.g. pulmonary hypertension, COPD)
• • Metabolic disease (incl. but not limited to Cushing disease, Diabetes)
• • Renal disease (by Chronic kidney disease criteria)
• • Active inflammatory bowel syndrome
• • Cancer
• • Pregnancy
• • Smoker
• • Any chronic medication use
• • Steroid treatment for the last six months or hormone replacement therapy
• • Coagulopathy
• • Musculoskeletal or neurologic disease
• • Know allergy against any of the studied substances
• • Inclusion in any other concurrent medical research study